$0.72
+0.00 (+0.07%)
Open$0.74
Previous Close$0.71
Day High$0.74
Day Low$0.65
52W High$4.66
52W Low$0.60
Volume—
Avg Volume116.2K
Market Cap3.79M
P/E Ratio—
EPS$-4.51
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+5,323.8% upside
Current
$0.72
$0.72
Target
$38.78
$38.78
$26.82
$38.78 avg
$44.92
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.63M | 2.53M | 2.93M |
| Net Income | 21.2K | 20.0K | 19.6K |
| Profit Margin | 0.8% | 0.8% | 0.7% |
| EBITDA | 30.9K | 30.5K | 37.6K |
| Free Cash Flow | 17.8K | 22.0K | 24.1K |
| Rev Growth | -5.2% | +23.9% | +20.0% |
| Debt/Equity | 0.27 | 0.26 | 0.26 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |